Clinical data from preliminary studies promisingly demonstrated an enhanced incretin effect with the synergistic co-activation of GIP and GLP-1 receptors when dually targeted in obese mice as well as T2DM subjects [11, 25, 35]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.